HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Eric P Krenning Selected Research

Tyr(3)- octreotate

3/2010Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
3/2010Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
6/2007Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.
5/2007Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
2/2007Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.
2/2007Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.
1/2005Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
1/2005Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
1/2005Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.
7/2004Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD

Eric P Krenning Research Topics

Disease

43Neoplasms (Cancer)
09/2010 - 04/2002
16Neuroendocrine Tumors (Neuroendocrine Tumor)
09/2010 - 04/2002
10Neoplasm Metastasis (Metastasis)
11/2007 - 06/2002
6Thyroid Neoplasms (Thyroid Cancer)
01/2007 - 06/2002
4Carcinoma (Carcinomatosis)
08/2009 - 03/2003
4Carcinoid Tumor (Carcinoid)
04/2008 - 08/2007
3Prostatic Neoplasms (Prostate Cancer)
07/2010 - 01/2007
3Diabetes Mellitus
05/2010 - 06/2003
3Proteinuria
05/2007 - 04/2002
3Pituitary Neoplasms (Pituitary Adenoma)
04/2007 - 12/2003
3Breast Neoplasms (Breast Cancer)
04/2004 - 03/2003
2Hypertension (High Blood Pressure)
05/2010 - 04/2002
2Hodgkin Disease (Hodgkin's Disease)
06/2009 - 04/2003
2Pheochromocytoma
04/2008 - 01/2007
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2006 - 08/2002
2Cardiomyopathies (Cardiomyopathy)
06/2003 - 09/2002
1Multiple Endocrine Neoplasia Type 1 (MEN I)
08/2010
1Thrombocytopenia (Thrombopenia)
03/2010
1Ovarian Neoplasms (Ovarian Cancer)
04/2008
1Vipoma (WDHA)
04/2008
1Autoimmune Diseases (Autoimmune Disease)
02/2008
1Adenocarcinoma
06/2007
1Starvation
06/2007
1Body Weight (Weight, Body)
05/2007
1Paraganglioma (Paragangliomas)
01/2007
1Kidney Failure (Renal Failure)
01/2007
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2007
1Myocardial Infarction
01/2006
1Left Ventricular Dysfunction
01/2006

Drug/Important Bio-Agent (IBA)

26Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
09/2010 - 04/2002
26Somatostatin Receptors (Somatostatin Receptor)IBA
09/2010 - 04/2002
16Peptide Receptors (Peptide Receptor)IBA
09/2010 - 12/2002
16Pentetic Acid (DTPA)FDA LinkGeneric
03/2010 - 04/2002
14Octreotide (Sandostatin)FDA LinkGeneric
03/2010 - 04/2002
12Tyr(3)- octreotateIBA
03/2010 - 04/2002
73-Tyr-octreotideIBA
03/2010 - 04/2002
6BombesinIBA
07/2010 - 12/2002
5PeptidesIBA
05/2010 - 01/2005
5yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acidIBA
03/2010 - 01/2005
5Radioisotopes (Radionuclides)IBA
07/2009 - 04/2002
4pentetreotide (OctreoScan)FDA Link
05/2010 - 04/2003
3HormonesIBA
09/2010 - 06/2007
3RadiopharmaceuticalsIBA
07/2009 - 02/2008
3folate-binding proteinIBA
04/2008 - 08/2007
3Folic Acid (Vitamin M)FDA LinkGeneric
04/2008 - 08/2007
3Lysine (L-Lysine)FDA Link
05/2007 - 12/2005
3CreatinineIBA
05/2007 - 04/2002
3Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
04/2007 - 12/2003
3Gastrin-Releasing PeptideIBA
01/2007 - 12/2002
2Bombesin Receptors (Bombesin Receptor)IBA
06/2010 - 01/2007
2Cholecystokinin (Pancreozymin)IBA
08/2009 - 07/2009
2Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA
07/2009 - 04/2008
2indium-111-octreotideIBA
07/2009 - 01/2005
2Substance PIBA
07/2009 - 01/2005
2pemetrexed (MTA)FDA Link
04/2008 - 08/2007
2NeurotensinIBA
06/2007 - 01/2005
2Dexamethasone (Maxidex)FDA LinkGeneric
01/2006 - 08/2002
2DobutamineFDA LinkGeneric
01/2006 - 09/2002
2Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2006 - 06/2003
2Cholecystokinin B ReceptorIBA
04/2004 - 03/2003
2minigastrinIBA
04/2004 - 03/2003
1N-acetyltalosaminuronic acid (NAT)IBA
08/2010
1Prostate-Specific Antigen (Semenogelase)IBA
07/2010
1Messenger RNA (mRNA)IBA
06/2010
1Testosterone (Sustanon)FDA Link
06/2010
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
06/2010
1thymidine 5'-triphosphate (TTP)IBA
03/2010
1NeuropeptidesIBA
07/2009
1GastrinsIBA
07/2009
1Vincristine (Oncovin)FDA LinkGeneric
06/2009
1Procarbazine (Matulane)FDA Link
06/2009
1MOPP protocolIBA
06/2009
1Vinblastine (Vinblastine Sulfate)FDA Link
06/2009
1Prednisone (Sone)FDA LinkGeneric
06/2009
1Dacarbazine (DIC)FDA LinkGeneric
06/2009
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2009
1Mechlorethamine (Nitrogen Mustard)FDA Link
06/2009
1Epirubicin (Ellence)FDA LinkGeneric
06/2009
1Bleomycin (Blenoxane)FDA LinkGeneric
06/2009
1arginylprolineIBA
06/2007
1glycylproline (Gly-Pro)IBA
06/2007
1hydroxide ionIBA
06/2007
1Amifostine (Ethyol)FDA LinkGeneric
05/2007
1Dopamine Receptors (Dopamine Receptor)IBA
04/2007
1Carbon MonoxideIBA
02/2007
1Protective AgentsIBA
01/2007
1InterferonsIBA
04/2006
1docetaxel (Taxotere)FDA Link
01/2006
1Atropine (Hyoscyamine)FDA LinkGeneric
01/2006
1LutetiumIBA
01/2006
1Prednisolone (Predate)FDA LinkGeneric
01/2006
1YttriumIBA
01/2006
1technetium Tc 99m 1,2- bis(bis(2- ethoxyethyl)phosphino)ethane (Myoview)FDA Link
01/2006

Therapy/Procedure

6Radiotherapy
09/2010 - 12/2002
6Drug Therapy (Chemotherapy)
05/2010 - 08/2002
4Heterologous Transplantation (Xenotransplantation)
06/2010 - 01/2007
3Aftercare (After-Treatment)
07/2009 - 04/2003
2Castration
06/2010 - 01/2007
1Salvage Therapy
03/2010
1Combination Drug Therapy (Combination Chemotherapy)
06/2009